Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Kezar Life Sciences logo — Pioneering first-in-class, small-molecule therapies for immu...

Kezar Life Sciences

Pioneering first-in-class, small-molecule therapies for immune-mediated and oncologic disorders

Founded 2015 United States South San Francisco, United States 71 employees Post-IPO Equity Total: $135.16M Health Care, Health and Wellness +1

General Information

Company Name Kezar Life Sciences
Founded Year 2015
Location United States South San Francisco, United States
Employees 71
Industries Health Care, Health and Wellness, Life Sciences
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Kezar Life Sciences. To contact Kezar Life Sciences, visit kezarlifesciences.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Kezar Life Sciences compare?

A PDF of Kezar Life Sciences and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Kezar Life Sciences soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Kezar Life Sciences

Kezar Life Sciences is a clinical-stage biotechnology company founded in 2015 in the United States, focusing on the development of novel, first-in-class, small-molecule therapies for immune-mediated and oncologic disorders. The company's slogan "Pioneering first-in-class, small-molecule therapies for immune-mediated and oncologic disorders" reflects their commitment to leveraging cutting-edge science and innovation to transform patient outcomes. Their approach involves harnessing master regulators of cellular function and inhibiting multiple drivers of disease via a single target, with the potential to create significant clinical impact in challenging-to-treat conditions. The company recently received a substantial $12.16M Post-IPO Equity investment on 03 October 2022, with Morningside Venture Investments participating as the lead investor. Kezar's ambitious therapeutic platforms have the potential to address a wide array of indications, offering hope for patients in need across various conditions within the Health Care, Health and Wellness, and Life Sciences sectors.

Business keywords: Autoimmune Disease, Immunology, Oncology, Drug Discovery, Drug Development, Clinical-stage Biotechnology, Small-molecule Therapies, Immune-mediated Disorders, Oncologic Disorders, Protein Homeostasis, Protein Degradation, Cellular Function, Master Regulators, Intracellular Regulators

Funding Rounds & Investors (5)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $12.16M 1
Morningside Venture Investments
03 Oct 2022
Post IPO Debt $50.00M 1
Oxford Finance LLC
10 Nov 2021
Post IPO Equity Undisclosed 1
Solasta Ventures
Solasta Ventures
01 Jan 2020
Series B $50.00M 7
Qiming Venture Partners Bay City Capital Omega Funds
Qiming Venture Partners, Bay City Capital +5
25 Jul 2017
Series A $23.00M -
05 Jun 2015

Kezar Life Sciences Alternatives & Competitors

View All Alternatives
Kezar Life Sciences vs
Orum Therapeutics
Orum Therapeutics United States

A public biotechnology company pioneering a novel class of protein degraders.

IPO
55 employees
Biotechnology, Health Care
Kezar Life Sciences vs
Tango Therapeutics
Tango Therapeutics United States

Targeting tumor suppressor loss to unmask vulnerabilities for the next generation of precision medic...

Post-IPO Equity
157 employees
Biotechnology, Health Care
Kezar Life Sciences vs
Immunic Therapeutics
Immunic Therapeutics United States

Immunic is a biotechnology company developing small molecule therapies for chronic inflammatory and...

Post-IPO Equity
91 employees
Biotechnology, Health and Wellness
View all alternatives

FAQ About Kezar Life Sciences

Pioneering first-in-class, small-molecule therapies for immune-mediated and oncologic disorders
Kezar Life Sciences was founded in 2015.
Kezar Life Sciences is headquartered in South San Francisco, United States.
Kezar Life Sciences operates in Health Care, Health and Wellness and Life Sciences. Its work centres on Autoimmune Disease, Immunology, Oncology and Drug Discovery.
Kezar Life Sciences has approximately 71 employees.
Kezar Life Sciences has completed 5 funding rounds, raising a total of $135.16M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Kezar Life Sciences include Orum Therapeutics, Tango Therapeutics, Immunic Therapeutics, Seismic Therapeutic, Pharvaris. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Kezar Life Sciences and Orum Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Kezar Life Sciences, https://bouncewatch.com/company/kezar-life-sciences, updated 24 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes